Physician profile
Christopher E Bassil
NPI 1952574709
$39,290.31
in general payments reported to CMS, 2019-2025
43 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $7,054 · 2021: $5,072 · 2022: $775 · 2023: $1,705 · 2024: $2,339 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $2,703 · Travel and Lodging: $2,456 · Consulting Fee: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,662.50 |
| Food and Beverage | $2,703.08 |
| Travel and Lodging | $2,455.68 |
| Consulting Fee | $227.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $23,421.48 | 2024-2025 | |
| Next Science LLC | $10,420.68 | 2020-2021 | |
| Medtronic, INC. | $1,175.13 | 2023-2024 | Interstim |
| Abbvie INC. | $893.18 | 2019-2025 | Lo Loestrin Fe, Ubrelvy |
| Baxter Healthcare | $569.14 | 2020-2025 | Perclot |
| Organon LLC | $233.38 | 2021-2025 | Nexplanon, Jada System |
| Astellas Pharma US INC | $220.23 | 2019-2024 | Veozah, Myrbetriq |
| Therapeuticsmd, INC. | $218.12 | 2021-2022 | |
| Amgen INC. | $208.58 | 2021-2025 | Evenity, Prolia |
| Abbott Laboratories | $204.75 | 2022-2023 | Freestyle Libre 3 |
| Evofem Biosciences, INC. | $174.39 | 2023-2025 | Phexxi, Solosec, Phexx |
| Merck Sharp & Dohme LLC | $124.44 | 2019-2021 | |
| Axonics, INC. | $121.98 | 2021-2024 | Axonics, Bulkamid |
| Hologic Sales and Service, LLC | $117.37 | 2019-2025 | Aptima |
| Mayne Pharma Commercial LLC | $111.37 | 2022-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $95.46 | 2020-2023 | Summit Doppler |
| Pfizer INC. | $92.61 | 2023 | |
| Biogen, INC. | $86.55 | 2024-2025 | Zurzuvae |
| Minerva Surgical, INC | $85.54 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.48 | 2019-2022 | |
| Duchesnay USA Incorporated | $58.47 | 2019 | |
| Millicent US INC | $57.62 | 2020-2025 | Femring, Intrarosa, Femlyv |
| Agile Therapeutics, INC. | $56.73 | 2021-2024 | Twirla |
| Myovant Sciences INC. | $51.85 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $50.68 | 2023-2024 | Myfembree |
| Exeltis, USA INC. | $43.05 | 2021-2023 | Slynd |
| Daiichi Sankyo INC. | $33.14 | 2020-2022 | |
| Vertex Pharmaceuticals Incorporated | $30.67 | 2025 | |
| Currax Pharmaceuticals LLC | $28.57 | 2021-2022 | |
| Novo Nordisk INC | $28.46 | 2023-2024 | Wegovy, Saxenda |
| Allergan, INC. | $26.34 | 2019-2020 | |
| Phadia US INC. | $22.73 | 2022 | |
| Convatec INC. | $17.45 | 2024 | |
| Medline Industries LP | $17.27 | 2021 | |
| Innovation Technologies INC | $16.91 | 2022 | |
| Gilead Sciences, INC. | $16.39 | 2019 | |
| Optumhealth Care Solutions, LLC | $16.31 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Avion Pharmaceuticals | $15.97 | 2020 | |
| Covidien LP | $15.64 | 2019 | |
| Scynexis, INC. | $13.23 | 2021 | |
| Lupin INC. | $12.52 | 2020 | |
| Becton, Dickinson and Company | $11.97 | 2022 | |
| Mylan Pharmaceuticals INC. | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bassil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.